Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 120

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 120
---
| (2) | The                                                                                           
 denominator is based on 34,426,355 shares of common stock outstanding as of November 25,      
 2025 (which includes the 131,909 Commitment Shares we issued to Yorkville on October 24,      
 2025), adjusted to include (i) the issuance of the number of shares set forth in the adjacent 
 column that we would have sold to Yorkville, assuming the average purchase price in the first 
 column and (ii) excludes the issuance of any Conversion Shares. The numerator is based on     
 the number of shares issuable under the SEPA as Advance Shares at the corresponding assumed   
 average purchase price set forth in the first column.                                         |

| (3) | The                                                                        
 closing sale price of our common stock on the Nasdaq on November 25, 2025. |

| 65 |

<div align='center'>DIVIDEND POLICY</div>

We have not declared or paid any cash dividends on our capital stock since our inception. We currently intend to retain future earnings, if any, and do not anticipate paying any cash dividends in the foreseeable future.

<div align='center'>MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</div>

Market Information

Our common stock is currently listed on the Nasdaq Capital Market under the symbol “JUNS.”

Holders of Common Stock

As of November 25, 2025, there were approximately 21 record holders of our common stock. The number of record holders does not include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.

We have not paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.

| 66 |

<div align='center'>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>

References in this prospectus to “we,” “us” or the “Company” refer to Jupiter Neurosciences, Inc. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this prospectus.

Overview

Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting CNS disorders and